BEAM Overview
Upcoming Projects (BEAM)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BEAM)
-
A Second View: Examining novel candidates for alpha-1 antitrypsin deficiency, including Beam Therapeutics’ BEAM-302 and Wave Life Sciences’ WVE-006
Tickers: WVE, BEAM
Executed On: Jan 22, 2026 at 09:00 AM EST -
Examining novel candidates for alpha-1 antitrypsin deficiency, including Beam Therapeutics’ BEAM-302 and Wave Life Sciences’ WVE-006
Tickers: WVE, BEAM
Executed On: Jan 20, 2026 at 01:30 PM EST -
Discussing Fulcrum Therapeutics' Phase 1b PIONEER Trial of Pociredir and Beam Therapeutics' Phase 1/2 clinical trial for BEAM-101 in Sickle Cell Disease.
Tickers: FULC, BEAM
Executed On: Nov 03, 2025 at 11:00 AM EST -
Discussing Beam Therapeutics' Phase 1/2 results for BEAM-302 for patients with AATD.
Ticker: BEAM
Executed On: May 21, 2025 at 12:00 PM EDT -
Discussing Beam's recent BEACON and ESCAPE data for BEAM-101 in Sickle Cell Disease presented at ASH 2024
Ticker: BEAM
Executed On: Jan 06, 2025 at 10:00 AM EST
Expired Projects (BEAM)
-
Analyzing the Phase 1/2 Study Results for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) from Beam Therapeutics
Ticker: BEAM
Execute By: Sep 30, 2025
Upcoming & Overdue Catalysts (BEAM)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (BEAM)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
